0001437749-20-023003.txt : 20201106 0001437749-20-023003.hdr.sgml : 20201106 20201106161056 ACCESSION NUMBER: 0001437749-20-023003 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201105 FILED AS OF DATE: 20201106 DATE AS OF CHANGE: 20201106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hanna John Walter JR CENTRAL INDEX KEY: 0001781127 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36156 FILM NUMBER: 201294519 MAIL ADDRESS: STREET 1: 6000 SHORELINE COURT STREET 2: SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERACYTE, INC. CENTRAL INDEX KEY: 0001384101 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 205455398 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 243-6300 MAIL ADDRESS: STREET 1: 6000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: CALDEROME INC DATE OF NAME CHANGE: 20061219 4 1 rdgdoc.xml FORM 4 X0306 4 2020-11-05 0001384101 VERACYTE, INC. VCYT 0001781127 Hanna John Walter JR 6000 SHORELINE COURT SUITE 300 SOUTH SAN FRANCISCO CA 94080 1 Chief Commercial Officer Common Stock 2020-11-05 4 M 0 3125 9.05 A 77434 D Common Stock 2020-11-05 4 M 0 3281 5.98 A 80715 D Common Stock 2020-11-05 4 S 0 3613 39.9962 D 77102 D Common Stock 2020-11-05 4 S 0 2660 41.5594 D 74442 D Common Stock 2020-11-05 4 S 0 133 42.0801 D 74309 D Stock Option (right to buy) 9.05 2020-11-05 4 M 0 3125 0 D 2027-03-02 Common Stock 3125 7292 D Stock Option (right to buy) 5.98 2020-11-05 4 M 0 3281 0 D 2028-03-01 Common Stock 3281 20782 D The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 11, 2020. Represents weighted average sales price. Sale prices for the transactions range from $39.95 to $40.78. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Represents weighted average sales price. Sale prices for the transactions range from $41.01 to $42.01. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Represents weighted average sales price. Sale prices for the transactions range from $42.05 to $42.13. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. The option became exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. /s/ Keith Kennedy, as Attorney-in-fact 2020-11-06